$NTRA

RABINOWITZ DANIEL sold $4.6M of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 16,800 shares of Natera, Inc. (NTRA) at an average of $272.29 ($266.79–$278.77, $4.57M total) across 12 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jul 7, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale (~16,800 shares; weighted avg ~$272.29) can influence short-term sentiment, but the 10b5-1 structure reduces interpretability as a directional signal.

02

Market read

Traders may monitor for follow-on insider activity, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not disclose any concurrent buy/sell by other insiders, nor any new guidance/clinical/regulatory update—so the signal is mostly sentiment/positioning, not valuation.

Relevance 5/10Novelty 5/10Timing: after-hours/next-session read-through from the latest Form 4 filing (filed 2026-07-06)

Background

The article is a primary-source SEC Form 4 insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera Form 4 shows Daniel Rabinowitz (Chief Legal Officer) sold ~$4.57M of NTRA shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a pre-arranged 10b5-1 plan, and the article provides no new company-specific operational or financial catalyst.

Market effects

Minimal; insider-sale disclosures typically do not reset sector expectations without accompanying fundamental news.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish information.

Key entities

  • Natera, Inc.

    Company whose shares were sold by an insider (Chief Legal Officer) under a 10b5-1 plan.

  • Daniel Rabinowitz

    Chief Legal Officer who executed the open-market sale disclosed on Form 4.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.